Lynx1 Capital Management »

Entrada Therapeutics shares owned by Lynx1 Capital Management

Quarter-by-quarter ownership of Entrada Therapeutics (TRDA) shares owned by Lynx1 Capital Management from 13F filings

Historical chart of Lynx1 Capital Management investment in Entrada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Entrada Therapeutics held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Entrada Therapeutics by Lynx1 Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.7M 212k 12.62
2025-12-31 $531k 52k 10.28

More positions owned by Lynx1 Capital Management

Stoke Therapeutics (STOK)
Gh Research Ordinary Shares (GHRS)
Cullinan Oncology (CGEM)
Agios Pharmaceuticals (AGIO)
Denali Therapeutics (DNLI)
C4 Therapeutics Com Stk (CCCC)
Korro Bio (KRRO)
Tscan Therapeutics (TCRX)
Xencor (XNCR)
Precision Biosciences Com New (DTIL)
Passage Bio Com New (PASG)
Neuphoria Therapeutics (NEUP)
Entrada Therapeutics (TRDA)
Cg Oncology (CGON)
Immatics SHS (IMTX)

View all positions for Lynx1 Capital Management

Top funds holding Entrada Therapeutics

Baker Bros. Advisors
5AM Venture Management
BlackRock
TCG Crossover Management
Vanguard Group
Vanguard Capital Management
Wellington Management Company
StepStone
Geode Capital Management
Millennium Management
State Street Corporation
Jones Hill Capital
Jacobs Levy Equity Management
Acadian Asset Management
Dimensional Fund Advisors

View all funds holding Entrada Therapeutics